ZTS Quote, Financials, Valuation and Earnings

Biomarin Pharmaceutical has a net margin of 28.56% compared to Zoetis's net margin of 14.23%. Zoetis's return on equity of 48% beat Biomarin Pharmaceutical's return on equity of 6.29%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 29.35%. On the other hand Biomarin Pharmaceutical has an analysts' consensus of $98.20 which suggests that it could grow by 45.74%. Given that Biomarin Pharmaceutical has higher upside potential than Zoetis, analysts believe Biomarin Pharmaceutical is more attractive than Zoetis.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Biomarin Pharmaceutical has a beta of 0.289, suggesting its less volatile than the S&P 500 by 71.112%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.06%. Biomarin Pharmaceutical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Biomarin Pharmaceutical pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Biomarin Pharmaceutical quarterly revenues of $745.7M. Zoetis's net income of $682M is higher than Biomarin Pharmaceutical's net income of $106.1M. Notably, Zoetis's price-to-earnings ratio is 30.70x while Biomarin Pharmaceutical's PE ratio is 40.35x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.16x versus 4.81x for Biomarin Pharmaceutical. Usually stocks with elevated PS ratios are considered overvalued.

Corcept Therapeutics has a net margin of 28.56% compared to Zoetis's net margin of 25.86%. Zoetis's return on equity of 48% beat Corcept Therapeutics's return on equity of 25.77%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 29.35%. On the other hand Corcept Therapeutics has an analysts' consensus of -- which suggests that it could grow by 50.25%. Given that Corcept Therapeutics has higher upside potential than Zoetis, analysts believe Corcept Therapeutics is more attractive than Zoetis.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Corcept Therapeutics has a beta of 0.555, suggesting its less volatile than the S&P 500 by 44.46%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.06%. Corcept Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Corcept Therapeutics pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than Corcept Therapeutics quarterly revenues of $182.5M. Zoetis's net income of $682M is higher than Corcept Therapeutics's net income of $47.2M. Notably, Zoetis's price-to-earnings ratio is 30.70x while Corcept Therapeutics's PE ratio is 39.56x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.16x versus 8.84x for Corcept Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

IDEXX Laboratories has a net margin of 28.56% compared to Zoetis's net margin of 23.87%. Zoetis's return on equity of 48% beat IDEXX Laboratories's return on equity of 57.37%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 29.35%. On the other hand IDEXX Laboratories has an analysts' consensus of $478.62 which suggests that it could grow by 14.49%. Given that Zoetis has higher upside potential than IDEXX Laboratories, analysts believe Zoetis is more attractive than IDEXX Laboratories.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison IDEXX Laboratories has a beta of 1.364, suggesting its more volatile than the S&P 500 by 36.364%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.06%. IDEXX Laboratories offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. IDEXX Laboratories pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are larger than IDEXX Laboratories quarterly revenues of $975.5M. Zoetis's net income of $682M is higher than IDEXX Laboratories's net income of $232.8M. Notably, Zoetis's price-to-earnings ratio is 30.70x while IDEXX Laboratories's PE ratio is 40.31x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.16x versus 9.09x for IDEXX Laboratories. Usually stocks with elevated PS ratios are considered overvalued.

Vertex Pharmaceuticals has a net margin of 28.56% compared to Zoetis's net margin of 37.71%. Zoetis's return on equity of 48% beat Vertex Pharmaceuticals's return on equity of -2.89%.

Zoetis has a consensus price target of $211.25, signalling upside risk potential of 29.35%. On the other hand Vertex Pharmaceuticals has an analysts' consensus of $492.97 which suggests that it could grow by 20.37%. Given that Zoetis has higher upside potential than Vertex Pharmaceuticals, analysts believe Zoetis is more attractive than Vertex Pharmaceuticals.

Zoetis has a beta of 0.891, which suggesting that the stock is 10.852% less volatile than S&P 500. In comparison Vertex Pharmaceuticals has a beta of 0.399, suggesting its less volatile than the S&P 500 by 60.102%.

Zoetis has a quarterly dividend of $0.43 per share corresponding to a yield of 1.06%. Vertex Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Zoetis pays 29.52% of its earnings as a dividend. Vertex Pharmaceuticals pays out -- of its earnings as a dividend. Zoetis's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Zoetis quarterly revenues are $2.4B, which are smaller than Vertex Pharmaceuticals quarterly revenues of $2.8B. Zoetis's net income of $682M is lower than Vertex Pharmaceuticals's net income of $1B. Notably, Zoetis's price-to-earnings ratio is 30.70x while Vertex Pharmaceuticals's PE ratio is 26.10x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Zoetis is 8.16x versus 10.03x for Vertex Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.